Guochun Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1196814/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Plasma exosomal RNAs have potential as both clinical biomarkers and therapeutic targets of dermatomyositis. Rheumatology, 2022, 61, 2672-2681.	1.9	12
2	Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies. BMC Pulmonary Medicine, 2022, 22, 14.	2.0	9
3	Clinical heterogeneities and prognoses of patients with myositis specific antibody negative dermatomyositis: a retrospective study in China. Clinical and Experimental Rheumatology, 2022, 40, 284-291.	0.8	2
4	Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome. Frontiers in Immunology, 2022, 13, 845988.	4.8	23
5	Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. RMD Open, 2022, 8, e001669.	3.8	4
6	Resistin Expression Is Associated With Interstitial Lung Disease in Dermatomyositis. Frontiers in Medicine, 2022, 9, 903887.	2.6	2
7	Serum levels of anti-transcriptional intermediary factor 1-Î ³ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis. Seminars in Arthritis and Rheumatism, 2022, 55, 152011.	3.4	4
8	Autoantibodies: Pathogenic or epiphenomenon. Best Practice and Research in Clinical Rheumatology, 2022, , 101767.	3.3	5
9	Clinical features, treatments and outcomes of calcinosis in adult patients with dermatomyositis: a single cohort study. Rheumatology, 2021, 60, 2958-2962.	1.9	7
10	Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110069.	2.7	3
11	Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clinical Rheumatology, 2021, 40, 2311-2317.	2.2	28
12	Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis. Arthritis Research and Therapy, 2021, 23, 15.	3.5	14
13	Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial. Rheumatology and Therapy, 2021, 8, 361-374.	2.3	3
14	The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study. Frontiers in Pharmacology, 2021, 12, 635654.	3.5	16
15	Characterization of genotype–phenotype correlation with MORC2 mutated Axonal Charcot–Marie–Tooth disease in a cohort of Chinese patients. Orphanet Journal of Rare Diseases, 2021, 16, 244.	2.7	3
16	The effects of infliximab in treating idiopathic inflammatory myopathies: A review article. Dermatologic Therapy, 2021, 34, e14976.	1.7	6
17	Muscle pathological features and extra-muscle involvement in idiopathic inflammatory myopathies with anti-mitochondrial antibody. Seminars in Arthritis and Rheumatism, 2021, 51, 741-748.	3.4	16
18	miR-18a-3p and Its Target Protein HuR May Regulate Myogenic Differentiation in Immune-Mediated Necrotizing Myopathy. Frontiers in Immunology, 2021, 12, 780237.	4.8	1

GUOCHUN WANG

#	Article	IF	CITATIONS
19	Interstitial Lung Disease Is a Major Characteristic of Patients Who Test Positive for Anti-PM/Scl Antibody. Frontiers in Medicine, 2021, 8, 778211.	2.6	6
20	Clinical heterogeneities and prognoses of patients with myositis specific antibody negative dermatomyositis: a retrospective study in China. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
21	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018. Neuromuscular Disorders, 2020, 30, 70-92.	0.6	148
22	Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232096841.	2.5	11
23	Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity. Mediators of Inflammation, 2020, 2020, 1-8.	3.0	4
24	Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome. Clinical Rheumatology, 2020, 39, 2417-2424.	2.2	14
25	Pituitary dysfunction in patients with ANCA associated vasculitis: prevalence, presentation, and outcomes. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232093063.	2.5	2
26	Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology, 2020, 59, 2829-2837.	1.9	59
27	Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217096.	0.9	10
28	Validation of new classification criteria of rheumatoid arthritis in an international multicentre study. Clinical and Experimental Rheumatology, 2020, 38, 841-847.	0.8	1
29	Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study. Clinical and Experimental Rheumatology, 2020, 38, 732-741.	0.8	4
30	Evaluation of 12 different assays for detecting ANCA in Chinese patients with GPA and MPA: a multicenter study in China. Clinical Rheumatology, 2019, 38, 3477-3483.	2.2	5
31	Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: Data from the largest single Chinese center. Respiratory Medicine, 2019, 155, 127-132.	2.9	17
32	The RIG-I pathway is involved in peripheral T cell lymphopenia in patients with dermatomyositis. Arthritis Research and Therapy, 2019, 21, 131.	3.5	17
33	Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data. BMC Musculoskeletal Disorders, 2019, 20, 174.	1.9	8
34	The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis. Frontiers in Immunology, 2019, 10, 159.	4.8	61
35	Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis. Journal of Immunology Research, 2019, 2019, 1-12.	2.2	14
36	The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Clinical Rheumatology, 2019, 38, 2171-2179.	2.2	41

GUOCHUN WANG

#	Article	IF	CITATIONS
37	Efficacy and Safety of Loxoprofen Hydrogel TransdermalÂPatch Versus Loxoprofen Tablet in Chinese Patients with Myalgia: A Double-Blind, Double-Dummy, Parallel-Group, Randomized, Controlled, Non-Inferiority Trial. Clinical Drug Investigation, 2019, 39, 369-377.	2.2	12
38	Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clinical Rheumatology, 2019, 38, 1655-1663.	2.2	32
39	The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. Current Opinion in Rheumatology, 2019, 31, 643-649.	4.3	32
40	Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients. Clinical Rheumatology, 2019, 38, 1425-1431.	2.2	6
41	Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study. Clinical Rheumatology, 2019, 38, 1047-1054.	2.2	13
42	The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial. Clinical Rheumatology, 2019, 38, 657-664.	2.2	12
43	Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study. Clinical and Experimental Rheumatology. 2019. 37. 227-234.	0.8	3
44	Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. Journal of Rheumatology, 2018, 45, 835-840.	2.0	23
45	Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies. American Journal of the Medical Sciences, 2018, 355, 48-53.	1.1	33
46	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Annals of the Rheumatic Diseases, 2018, 77, 30-39.	0.9	183
47	Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study. Clinical Rheumatology, 2018, 37, 597-605.	2.2	21
48	Disability and healthâ€related quality of life in Chinese patients with rheumatoid arthritis: A crossâ€sectional study. International Journal of Rheumatic Diseases, 2018, 21, 1709-1715.	1.9	16
49	Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis. Modern Rheumatology, 2017, 27, 122-129.	1.8	30
50	Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies. Journal of Rheumatology, 2017, 44, 1051-1057.	2.0	123
51	Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Scientific Reports, 2017, 7, 188.	3.3	65
52	Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. International Journal of Rheumatic Diseases, 2017, 20, 252-260.	1.9	6
53	Response to: â€~Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria' by Cavagnaet al. Annals of the Rheumatic Diseases, 2017, 77, annrheumdis-2017-212382.	0.9	2
54	Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Research and Therapy, 2017, 19, 259.	3.5	134

GUOCHUN WANG

#	Article	IF	CITATIONS
55	Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. Scientific Reports, 2016, 6, 27479.	3.3	29
56	Comparison of three classification criteria of rheumatoid arthritis in an inception early arthritis cohort. Clinical Rheumatology, 2016, 35, 2397-2401.	2.2	10
57	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmunity Reviews, 2016, 15, 983-993.	5.8	105
58	HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease. PLoS ONE, 2016, 11, e0161436.	2.5	21
59	Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies. PLoS ONE, 2015, 10, e0141616.	2.5	66
60	Discovery of new biomarkers of idiopathic inflammatory myopathy. Clinica Chimica Acta, 2015, 444, 117-125.	1.1	22
61	The impact of rheumatoid arthritis on work capacity in Chinese patients: a cross-sectional study. Rheumatology, 2015, 54, 1478-1487.	1.9	16
62	The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clinical Rheumatology, 2015, 34, 2097-2103.	2.2	47
63	The performance of MRI in detecting subarticular bone erosion of sacroiliac joint in patients with spondyloarthropathy: A comparison with X-ray and CT. European Journal of Radiology, 2014, 83, 2058-2064.	2.6	14
64	Factors Predicting Malignancy in Patients with Polymyositis and Dermatomyostis: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e94128.	2.5	96